Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

40.70 +0.00 (+0.00%)

Streaming Delayed Price Updated: 11:50 AM EDT, Apr 8, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,813,920
Open	40.66
Bid (Size)	40.70 (9,900)
Ask (Size)	40.71 (4,800)
Prev. Close	40.70
Today's Range	40.65 - 40.73
52wk Range	16.10 - 40.77
Shares Outstanding	116,457,008
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Halper Sadeh LLC is Investigating Whether APLS, CNTA, KZR, EQH are Obtaining Fair Deals for their Shareholders

April 07, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Shareholder Alert: Ademi LLP investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

April 07, 2026

From Ademi LLP

Via GlobeNewswire

Performance

YTD	+57.4%	+57.4%
1 Month	+103.6%	+103.6%
3 Month	+70.0%	+70.0%
6 Month	+61.4%	+61.4%
1 Year	+105.6%	+105.6%

More News

Why Biogen Stock Got Mashed on Monday ↗

April 06, 2026

Via The Motley Fool

Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology

April 06, 2026

Via MarketMinute

Apellis Pharmaceuticals (NASDAQ:APLS) Emerges as a Prime Affordable Growth (GARP) Candidate ↗

April 02, 2026

Via Chartmill

Apellis Pharmaceuticals Inc (NASDAQ:APLS) Reports Q4 2025 Earnings Beat Amid Mixed Revenue Results ↗

February 24, 2026

Via Chartmill

The Coiled Spring: Why Small-Caps are Poised for a Generational Productivity-Led Surge

April 03, 2026

Via MarketMinute

Halper Sadeh LLC is Investigating Whether APLS, CNTA, EQH, VYNE are Obtaining Fair Deals for their Shareholders

April 02, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success

April 01, 2026

Via MarketMinute

Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS

March 31, 2026

From Kahn Swick & Foti

Via Business Wire

Why Biogen Stock Sank While the Market Soared on Thursday ↗

March 31, 2026

Via The Motley Fool

Halper Sadeh LLC is Investigating Whether APLS, CNTA, BIRD, WBD are Obtaining Fair Deals for their Shareholders

March 31, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases

March 31, 2026

Via MarketMinute

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

March 31, 2026

Via Chartmill

Spotlight Movers: APLS, VTIX, ELAB, ARTL Fuel Multi-Sector Momentum

March 31, 2026

Via AB Newswire

These stocks are making the most noise in today's session. ↗

March 31, 2026

Via Chartmill

Which stocks are experiencing notable movement on Tuesday? ↗

March 31, 2026

Via Chartmill

The market is filled with gapping stocks in Tuesday's session. ↗

March 31, 2026

Via Chartmill

Discover the top movers in Tuesday's pre-market session. ↗

March 31, 2026

Via Chartmill

APLS Stock Alert: Halper Sadeh LLC is Investigating Whether Apellis Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

March 31, 2026

From Halper Sadeh LLC

Via Business Wire

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

March 31, 2026

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗

March 21, 2026

Via The Motley Fool

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

March 02, 2026

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis (APLS) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Via The Motley Fool

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

February 24, 2026

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Apellis Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Apellis Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Apellis Pharmaceuticals, Inc. - Common Stock trade on?

Apellis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock is APLS on the Nasdaq Stock Market

What is the current price of Apellis Pharmaceuticals, Inc. - Common Stock?

The current price of Apellis Pharmaceuticals, Inc. - Common Stock is 40.70

When was Apellis Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Apellis Pharmaceuticals, Inc. - Common Stock was at 04/08/26 11:50 AM ET

What is the market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock is 4.74B

How many shares of Apellis Pharmaceuticals, Inc. - Common Stock are outstanding?

Apellis Pharmaceuticals, Inc. - Common Stock has 5B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.